Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

NCT05738616 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT: Lenvatinib combined with TACE and Camrelizumab

Sponsor

Wen Tianfu